Phantomics Signs MOU with Flownix to Bring Cardiac MRI to More Patients

Phantomics (CEOs Byoung Wook Choi and Pan Ki Kim), a specialist in cardiac MRI image-analysis solutions, announced on January 24 that it has signed a memorandum of understanding (MOU) with Flownix, a developer of MRI-based blood-flow analysis software, to advance cardiac MRI technology and broaden its adoption. Under the MOU, the two companies will pursue joint research and development and marketing cooperation to enhance cardiac MRI analysis solutions and expand their use in clinical practice.
Cardiovascular disease is the leading cause of death worldwide and the second-leading cause in Korea. According to the World Health Organization, about 17.9 million people die from cardiovascular disease every year. Because early detection, diagnosis and appropriate treatment can significantly reduce mortality, accurate early diagnosis and prevention are essential.
Cardiac MRI is a non-invasive examination that evaluates the structure and function of the heart in detail with high-resolution images. It involves no radiation exposure and tends to be more accurate than other tests; according to research from the American College of Cardiology, cardiac MRI shows more than 90% accuracy in diagnosing myocardial infarction. However, long scan and analysis times and the high level of expertise required have hindered wider adoption. Phantomics and Flownix have been developing innovative technologies to solve these problems.
Phantomics developed Myomics, an AI-based cardiac MRI analysis solution that shortens image analysis to under two minutes. It is used at more than 20 tertiary hospitals in Korea and overseas, including in the United States and Singapore. Flownix is developing 4D flow MRI software that precisely evaluates cardiovascular hemodynamics from MRI images, a technology expected to visualize and quantify complex blood-flow patterns and improve diagnostic accuracy for cardiovascular disease.
"By combining the two companies' technologies, we will be able to develop more accurate and efficient cardiac MRI analysis solutions and accelerate the wider adoption of cardiac MRI," said Pan Ki Kim, CEO of Phantomics. Hojin Ha, CEO of Flownix, said that combining Phantomics' AI-based image analysis with Flownix's blood-flow analysis could open a new paradigm in cardiovascular diagnosis. Professor Dong Hyun Yang of Asan Medical Center added that the convergence of the two technologies would greatly improve the accuracy and efficiency of cardiovascular diagnosis, leading to better patient survival and lower healthcare costs.